These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1911205)

  • 1. The relationship between risk of death from clinical stage 1 cutaneous melanoma and thickness of primary tumour: no evidence for steps in risk. Scottish Melanoma Group.
    Keefe M; Mackie RM
    Br J Cancer; 1991 Sep; 64(3):598-602. PubMed ID: 1911205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
    McKenna DB; Lee RJ; Prescott RJ; Doherty VR
    Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease.
    Meyskens FL; Berdeaux DH; Parks B; Tong T; Loescher L; Moon TE
    Cancer; 1988 Sep; 62(6):1207-14. PubMed ID: 3409189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases. A multivariate regression analysis.
    Søndergaard K; Schou G
    Virchows Arch A Pathol Anat Histopathol; 1985; 406(2):179-95. PubMed ID: 3923697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action profiles of predictors of death and survival time in stage I malignant melanoma.
    Helfenstein U; Schuler G; Morf S; Schuler D
    Dermatology; 1996; 192(1):1-7. PubMed ID: 8832942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.
    Karjalainen JM; Eskelinen MJ; Kellokoski JK; Reinikainen M; Alhava EM; Kosma VM
    Br J Cancer; 1999 Feb; 79(5-6):895-902. PubMed ID: 10070887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma in people aged 65 and over in Scotland, 1979-89.
    McHenry PM; Hole DJ; MacKie RM
    BMJ; 1992 Mar; 304(6829):746-9. PubMed ID: 1571680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is initial excision of cutaneous melanoma by General Practitioners (GPs) dangerous? Comparing patient outcomes following excision of melanoma by GPs or in hospital using national datasets and meta-analysis.
    Murchie P; Amalraj Raja E; Brewster DH; Iversen L; Lee AJ
    Eur J Cancer; 2017 Nov; 86():373-384. PubMed ID: 29100192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status.
    MacKie RM; Hole DJ
    BMJ; 1996 May; 312(7039):1125-8. PubMed ID: 8620127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden.
    Thörn M; Pontén F; Bergström R; Sparén P; Adami HO
    J Natl Cancer Inst; 1994 May; 86(10):761-9. PubMed ID: 8169974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous malignant melanoma in south-east Scotland.
    Pondes S; Hunter JA; White H; McIntyre MA; Prescott RJ
    Q J Med; 1981; 50(197):103-21. PubMed ID: 7267966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
    Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
    Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94. The Scottish Melanoma Group.
    MacKie RM; Hole D; Hunter JA; Rankin R; Evans A; McLaren K; Fallowfield M; Hutcheon A; Morris A
    BMJ; 1997 Nov; 315(7116):1117-21. PubMed ID: 9374883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of tumour thickness in cutaneous malignant melanoma.
    Jeffrey I; Royston P; Sowter C; Slavin G; Price A; Pomerance A; Goolamali S; Pinto D
    J Clin Pathol; 1983 Jan; 36(1):51-6. PubMed ID: 6822677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous malignant melanoma in West Yorkshire: I. A prospective study of variables, survival and prognosis.
    Eastwood J; Baker TG
    Br J Cancer; 1983 Nov; 48(5):645-55. PubMed ID: 6639857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thick melanoma: the challenge persists.
    Murray CS; Stockton DL; Doherty VR
    Br J Dermatol; 2005 Jan; 152(1):104-9. PubMed ID: 15656809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Survival analysis in patients with cutaneous malignant melanoma].
    Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
    Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with a high tumour thickness in patients with melanoma.
    Baumert J; Plewig G; Volkenandt M; Schmid-Wendtner MH
    Br J Dermatol; 2007 May; 156(5):938-44. PubMed ID: 17381454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the thickness of uninvolved dermis beneath cutaneous malignant melanoma: the ratio of uninvolved dermis to tumour thickness (DT:TT) as a prognostic index.
    Saxby PJ; Griffiths RW; Corbishley CM; Briggs JC
    Br J Plast Surg; 1984 Oct; 37(4):496-500. PubMed ID: 6498387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model.
    Sahin S; Rao B; Kopf AW; Lee E; Rigel DS; Nossa R; Rahman IJ; Wortzel H; Marghoob AA; Bart RS
    Cancer; 1997 Oct; 80(8):1426-31. PubMed ID: 9338466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.